Company empowers ADME, hepatobiology, and toxicity research toward the goal of reducing the risk of adverse drug effects

BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced the opening of its Hepatocyte Grants Program and that it is actively reviewing research proposals. As a leader in the field, BioIVT is committed to supporting groundbreaking research by providing free access to select lots of the company’s highly characterized cryosuspension hepatocytes that are ideally suited to non-CYP metabolism studies and other novel applications.

Co-administered medications affecting the same enzymatic pathways may result in interactions that can disrupt therapeutic benefits or even lead to potentially dangerous outcomes. Since most of the current drugs on the market are metabolized via CYP enzymes, developing drugs metabolized by non-CYP enzymes can lower the risk of these adverse interactions and effects. As such, this initiative aims to empower innovative projects in non-CYP research with a focus on drug metabolism and other ADME-related research while also encouraging the exploration of new areas in hepatobiology and toxicity.

With over 40 years of experience in delivering high-quality personalized biospecimen solutions and research services to the life science and diagnostic industries, BioIVT continues to aid in driving medical breakthroughs, including important academic and industry research.

“BioIVT continues to pioneer critical research, including recent findings around the evaluation of CYP- and non-CYP enzyme-based metabolism of drug candidates in drug development and drug-drug interactions,” said Tina Mueller, Scientific Advisor, ADMET Services at BioIVT. “As a company, our primary focus continues to be serving as a trusted partner in ELEVATING SCIENCE^®, empowering customers to drive effective and efficient drug development. We’re honored to assist researchers through our grant program to support accelerating medical breakthroughs.”

To learn more about the Hepatocyte Grants Program and to apply, visit the call for proposals here: https://bioivt.com/scientific-affairs-submit-a-proposal

About BioIVT

BioIVT enables smarter science and accelerates medical breakthroughs by delivering high-quality personalized biospecimen solutions and research services to the life science and diagnostic industries. We specialize in control and disease state samples including human and animal tissues or preparations, ADME products and research services, cell and gene therapy products, blood, and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in ELEVATING SCIENCE^®. For more information, please visit www.bioivt.com or follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250708749872/en/